Steroid use after the Kasai procedure for biliary atresia.
BACKGROUND
The aim of this study was to describe patients undergoing the Kasai procedure at children's hospitals, evaluate outcomes, and analyze the association of these outcomes with systemic steroid use.


METHODS
Biliary atresia patients (International Classification of Diseases, Ninth Revision, code 751.61) who underwent Kasai procedures at freestanding children's hospitals in the Pediatric Health Information System database from 2003 to 2008 were identified. Descriptive characteristics were examined, and regression analyses were used to determine whether postoperative steroid use was associated with length of stay, mortality, or cholangitis.


RESULTS
Of the 516 children identified (40% male, 50% aged < 2 months), 239 (46%) received perioperative steroids. The mean total and postoperative lengths of stay were 14.5 +/- 19.7 and 11.3 +/- 16.3 days, respectively. Postoperative steroid use was significantly associated with a 3.5-day decrease in postoperative length of stay (95% confidence interval, .03-6.97).


CONCLUSIONS
Perioperative steroids after the Kasai procedure are associated with shorter postoperative length of stay. Work is needed to ascertain whether this relationship is causal.
Lao
Oliver B
OB
Department of Surgery, Seattle Children's Hospital, Seattle, WA, USA. olao@uw.edu
Larison
Cindy
C
Garrison
Michelle
M
Healey
Patrick J
PJ
Goldin
Adam B
AB
D001656:Biliary Atresia / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery*; D015331:Cohort Studies; D016001:Confidence Intervals; D016208:Databases, Factual; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D017052:Hospital Mortality / Q000639:trends; D006776:Hospitals, Pediatric; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007902:Length of Stay; D008297:Male; D011171:Portoenterostomy, Hepatic / Q000009:adverse effects / Q000379:methods*; D011182:Postoperative Care / Q000379:methods; D011336:Probability; D012189:Retrospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D013256:Steroids / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D013256:Steroids
J Pediatr. 2006 Apr;148(4):467-474
16647406
Am J Gastroenterol. 2008 Mar;103(3):712-9
18177447
J Pediatr Surg. 2001 Jan;36(1):80-5
11150442
J Pediatr Surg. 1997 Jul;32(7):1103-6; discussion 1106-7
9247243
Lancet. 1989 Feb 25;1(8635):421-3
2563796
J Pediatr Surg. 2003 Mar;38(3):406-11
12632357
J Pediatr Surg. 2006 Jan;41(1):99-103; discussion 99-103
16410116
Eur J Pediatr Surg. 2007 Jun;17(3):180-3
17638156
Hepatology. 2007 Dec;46(6):1821-7
17935230
J Pediatr Surg. 1985 Dec;20(6):693-5
4087100
Hepatology. 2006 Jul;44(1):75-84
16799986
J Pediatr Surg. 2004 Dec;39(12):1800-2
15616934
J Pediatr Surg. 2003 Apr;38(4):590-3
12677572
Lancet. 2000 Jan 1;355(9197):25-9
10615887